Literature DB >> 27434880

ABCB1 SNP rs4148738 modulation of apixaban interindividual variability.

Claudia Dimatteo1, Giovanna D'Andrea1, Gennaro Vecchione2, Oriana Paoletti3, Giovanni Luca Tiscia2, Rosa Santacroce1, Michele Correale4, Natale Brunetti4, Elvira Grandone2, Sophie Testa3, Maurizio Margaglione5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27434880     DOI： 10.1016/j.thromres.2016.07.005

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  10 in total

1.  Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Authors:  Mariana Babayeva; Brigitte Azzi; Zvi G Loewy
Journal:  Methods Mol Biol       Date:  2022

2.  Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.

Authors:  Camille Lenoir; Jean Terrier; Yvonne Gloor; Pauline Gosselin; Youssef Daali; Christophe Combescure; Jules Alexandre Desmeules; Caroline Flora Samer; Jean-Luc Reny; Victoria Rollason
Journal:  J Pers Med       Date:  2022-03-24

3.  Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.

Authors:  Markus Gulilat; Denise Keller; Bradley Linton; A Demetri Pananos; Daniel Lizotte; George K Dresser; Jeffrey Alfonsi; Rommel G Tirona; Richard B Kim; Ute I Schwarz
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

4.  Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.

Authors:  Adela-Nicoleta Roşian; Ştefan Horia Roşian; Bela Kiss; Maria Georgia Ştefan; Adrian Pavel Trifa; Camelia Diana Ober; Ovidiu Anchidin; Anca Dana Buzoianu
Journal:  Genes (Basel)       Date:  2020-04-17       Impact factor: 4.096

5.  Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry.

Authors:  Hyeon-Cheol Jeong; Tae-Eun Kim; Kwang-Hee Shin
Journal:  Transl Clin Pharmacol       Date:  2019-03-27

Review 6.  Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Johanna Raymond; Laurent Imbert; Thibault Cousin; Thomas Duflot; Rémi Varin; Julien Wils; Fabien Lamoureux
Journal:  J Pers Med       Date:  2021-01-11

7.  Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation.

Authors:  Sutee Limcharoen; Manat Pongchaidecha; Piyarat Pimsi; Sarawuth Limprasert; Juthathip Suphanklang; Weerayuth Saelim; Wichai Santimaleeworagun; Pornwalai Boonmuang
Journal:  Biomedicines       Date:  2022-08-18

8.  Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events.

Authors:  Sofia Attelind; Pär Hallberg; Mia Wadelius; Anna-Karin Hamberg; Agneta Siegbahn; Christopher B Granger; Renato D Lopes; John H Alexander; Lars Wallentin; Niclas Eriksson
Journal:  Front Genet       Date:  2022-09-14       Impact factor: 4.772

9.  Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.

Authors:  Alexander Valerevich Kryukov; Dmitry Alekseevich Sychev; Denis Anatolevich Andreev; Kristina Anatolievna Ryzhikova; Elena Anatolievna Grishina; Anastasia Vladislavovna Ryabova; Mark Alekseevich Loskutnikov; Valeriy Valerevich Smirnov; Olga Dmitrievna Konova; Irina Andreevna Matsneva; Pavel Olegovich Bochkov
Journal:  Pharmgenomics Pers Med       Date:  2018-03-22

Review 10.  Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Authors:  Natalia Cullell; Caty Carrera; Elena Muiño; Nuria Torres; Jerzy Krupinski; Israel Fernandez-Cadenas
Journal:  Oncotarget       Date:  2018-06-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.